Effects of levocarnitine oral solution on the plasma N-terminal probrain natriuretic peptide levels in children with acute lymphocytic leukemia treated by daunorubicin

Abstract

Abstract: AIM: To explore the value of N-terminal pro-brain natriuretic peptide (NT-pro BNP) in diagnosing the myocardiopathy induced by daunorubicin (DNR) and the more effective cardiac-protection drugs by investigating the changes of the NT-pro BNP levels after administrating DNR in children with acute lymphocytic leukemia. METHODS: Twenty-two children with acute lymphocytic leukemia who treated with DNR containing vincristine, L-asparaginase, prednisone, were randomly divided into two groups. The therapy group received L-CN as the cardiac-protection drug and the control group without protecting heart drug during chemotherapy with DNR. The level of NT-pro BNP in plasma was measured by immunoassay before and after using DNR and the cardiac troponin I(cTnI) and cardiac muscle enzyme (LDH1, CPK-MB) and ECG were detected before and after chemotherapy. RESULTS: The level of NT-pro BNP in plasma was increased from (53±11) pg/mL to (162±27) pg/mL (P <0.01) in the therapy group after chemotherapy and which in the control group was increased from (51±10) pg/mL to (194±38) pg/mL (P <0.01). There was no significant difference in the level of NT-pro BNP before chemotherapy between two groups. The level of NT-pro BNP in plasma was lower in the therapy group than that in the control group(P <0.05). The improving condition of the level of NT-pro BNP in the therapy group was better than that in the control group after chemotherapy. There were no significant difference in the ECG and cTnI and LDH1, CPK-MB in two groups before and after chemotherapy. CONCLUSION: NT-pro BNP can be served as a good indicator for DNR-induced myocardiopathy. Compared with control group, the improving condition of NT-pro BNP is obvious treated with levocarnitine.

Key words: levocarnitine, daunorubicin, peptide fragments, natriuretic peptide, brain, acute leukemia, child

CLC Number:

R979.1

WANG Ju-xiang, ZHU Xin-bo, ZENG Wei-wei, QIAN Jiang-chao, ZHOU Hai-xia, HUANG Zhen, FANG Xi-min, XU Xia, LI Yuan. Effects of levocarnitine oral solution on the plasma N-terminal probrain natriuretic peptide levels in children with acute lymphocytic leukemia treated by daunorubicin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1052-1055.

References

[1] Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury[J]. Semin Oncol, 2006, 33(3 Suppl 8): 8-14.
[2] 中华医学会儿科学分会血液学组.儿童急性淋巴细胞性白血病诊治建议[J]. 中华儿科杂志, 2006, 44(5): 392-395.
[3] 刘德新. 药物性心肌病1 例[J]. 实用儿科临床杂志, 2003, 18(3): 231.
[4] Elliott P.Pathogenesis of cardiotoxicity induced by anthracyclines[J]. Semin Oncol, 2006, 33(3 Suppl 8): S2-S7.
[5] Iwanaga Y, Nishi I, Furuichi S, et al.B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart fai1ure: comparison between systolic and diastolic heart failure[J]. J Am Coil Cardiol, 2006, 47(4): 742-748.
[6] Mir TS, Marohn S, Laer S, et a1.P1asma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure[J]. Pediatrics, 2002, 110(6): e76.
[7] 武育蓉, 陈树宝, 黄美蓉.氨基末端脑利钠肽前体在室间隔缺损合并心力衰竭诊断中的价值[J]. 中华儿科杂志, 2005, 43(3): 161-164.
[8] Germanakis I, KalmantiM, Parthenakis F, et al. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines[J]. Int J Cardiol, 2006, 108(2): 212-215.
[9] Simpson C, Herr H, Courville KA.Concurrent therapies that protect against doxorubicin-induced cardiomyopathy[J]. Clin J Oncol Nurs, 2004, 8(5): 497-501.
[10] Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies[J]. Br J Haematol, 2005, 131(5): 56l-578.
[11] Hong YM, Kim HS, Yoon HR.Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine[J]. Pediatr Res, 2002, 51(2): 249-255.

[1]	DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi. Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	QI Linling, LIU Shourong. Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.
[4]	XU Wei, CHEN Feng, YE Zhijun. Effectss of hyperoside on traumatic brain injury rats by regulating RhoA/ROCK signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 383-390.
[5]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[6]	LI Jiajia, CHEN Mengmeng, WANG Ruixian, HUANG Mengmeng, LI Jun, SHANGGUAN Wangning. Effects of alfentanil on tracheal intubation during tonsillectomy in children: A randomized double-blind study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 184-189.
[7]	FAN Di, SHI Cuina, YANG Qingqing, JI Muhuo. Research progress on effects of sevoflurane anesthesia on developing brain [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1333-1339.
[8]	YANG Liu, LUO Ailin, LI Shiyong. Advance of general anesthetics-induced developing brain injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1381-1390.
[9]	PAN Rongrong, ZHI Yinghao, JIN Yongxi, ZHOU Xiahui. Influences of theaflavins on neuronal apoptosis and blood-brain barrier in rats with cerebral hemorrhage by regulating CaMKK2/AMPK signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1240-1246.
[10]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[11]	WANG Yuanyuan, HONG Yu, ZHANG Lei, YIN Fangxiong, LEI Ting, ZHU Xi. Establishment and application of DUE criteria for human albumin in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 653-661.
[12]	XUAN Miaoyan, XU Zhen. Correlation between changes of intestinal flora in children with Kawasaki disease and the levels of specific transcription factors RORγt, FOXP3 and T lymphocyte subsets [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 154-160.
[13]	ZHONG Kailong, WANG Yongsheng, CHEN Fang, YE Yanrong. Exploration and expectation on treatment strategies of central nervous system diseases based on transporters at blood-brain barrier [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 953-960.
[14]	ZHANG Gaojiao, WANG Xinxin, ZHOU Jia, WANG Leilei, DAI Qinxue. Ginsenoside Rb1 protects brain through Cav-1 for mice with cerebral ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 265-270.
[15]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.